Xenon Pharmaceuticals Inc.

What they do

Xenon discovers and develops ion channel modulators, led by azetukalner, a Kv7 potassium channel opener being studied in focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS), major depressive disorder (MDD) and bipolar depression (BPD). Earlier-stage candidates include Nav1.7 (XEN1701, XEN1720) and Kv7 (XEN1120) programs for pain, and a Nav1.1 program in IND-enabling studies for Dravet Syndrome. It also has a partnered Phase 1 program, NBI-921355, with Neurocrine Biosciences. The company has never generated product sales revenue.

Revenue drivers

• Collaboration revenue — The only reported revenue source: $7.5 million recognized in 2025 from collaboration agreements, versus zero in 2024 and 2023.
• Azetukalner in FOS — Not yet revenue-generating; NDA submission in FOS is on track for Q3 2026. Phase 3 X-TOLE2 randomized 380 patients, with topline anticipated in early March 2026.
• Azetukalner in other indications — No revenue today. X-ACKT (PGTCS) and X-TOLE3 (ex-U.S. regulatory support) continue to enroll; X-NOVA2/X-NOVA3 (MDD) and X-CEED (BPD) are also ongoing.
• Partnered program (Neurocrine) — Phase 1 study ongoing for NBI-921355, a Nav1.2/Nav1.6 inhibitor for certain epilepsies; no product revenue recorded.

Recent performance

Xenon reported no revenue in the quarters ended September 30, 2025, December 31, 2025, March 31, 2026 and June 30, 2026. Full-year 2025 revenue was $7.5 million from collaboration agreements, compared with no revenue in 2024 and 2023. The net loss widened to $345.9 million in 2025 from $234.3 million in 2024 and $182.4 million in 2023, with diluted EPS of -$4.36 in 2025. Operating cash use increased to $279.1 million in 2025 from $181.4 million in 2024. As of June 30, 2026, total assets were $1.30 billion against total liabilities of $53.4 million, with $119.5 million in cash and cash equivalents and $811.2 million in marketable securities.

Strategy

Management aims to build a fully integrated biopharmaceutical company that discovers, develops and commercializes therapeutics for neurological and psychiatric disorders. Near-term priority is the Q3 2026 NDA submission for azetukalner in FOS, following a completed pre-NDA meeting with the FDA. It is funding Phase 3 expansion into PGTCS and neuropsychiatry (MDD, BPD) and advancing pain candidates XEN1701, XEN1720 and XEN1120 toward Phase 2 in acute pain. The company states it will need substantial additional capital and expects operating expenses to increase, particularly to prepare for a potential azetukalner commercial launch.

Risks

• Dependence on azetukalner — The business substantially depends on azetukalner; failure to obtain approval for or commercialize it would materially harm the company.
• No product revenue and continuing losses — Xenon has no approved products and no product sales, with net losses of $345.9 million in 2025 and an accumulated deficit of $1,245.4 million as of December 31, 2025.
• Need for additional capital — The company will need to raise additional funding that may not be available on acceptable terms, which could force delays or termination of development programs.
• Clinical and regulatory uncertainty — Clinical studies may fail to show adequate safety or efficacy, and FDA, EMA and other approval processes are lengthy and unpredictable.

Outlook

Management says the NDA submission for azetukalner in FOS remains on track for Q3 2026 and that X-TOLE2 data have been well received by healthcare providers. X-TOLE3 enrollment outside Japan is expected to complete in 2026, while X-ACKT continues to enroll. Topline data from the Phase 3 X-NOVA2 study in MDD are expected in H1 2027. Phase 1 studies of XEN1701 (Nav1.7) and XEN1120 (Kv7) are expected to complete in H2 2026, and a Phase 1 study of a second Nav1.7 candidate, XEN1720, is underway.